132 related articles for article (PubMed ID: 1823626)
1. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
Wakamatsu K; Ito S; Horikoshi T
Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
[TBL] [Abstract][Full Text] [Related]
2. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
3. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
4. Melanin-related metabolites in urine of B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1988; 68(5):385-9. PubMed ID: 2461020
[TBL] [Abstract][Full Text] [Related]
5. Some indolic compounds as markers of the melanocyte activity.
Hansson C
Acta Derm Venereol Suppl (Stockh); 1988; 138():1-60. PubMed ID: 3176811
[TBL] [Abstract][Full Text] [Related]
6. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese.
Wakamatsu K; Ito S
Pigment Cell Res; 1995 Jun; 8(3):132-4. PubMed ID: 7567788
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
8. The stability of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in human urine.
Kågedal B; Lenner L; Arstrand K; Hansson C
Pigment Cell Res; 1992; Suppl 2():304-7. PubMed ID: 1409435
[TBL] [Abstract][Full Text] [Related]
9. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
10. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1990; 70(5):367-72. PubMed ID: 1980967
[TBL] [Abstract][Full Text] [Related]
11. Urinary excretion of melanocytic metabolites in fertile women.
Carstam R; Hansson C; Rorsman H; Rosengren E; Sjöberg NO; Wirestrand LE
Acta Derm Venereol; 1985; 65(6):543-5. PubMed ID: 2420122
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid: differences between pigmented and albino mice.
Ekelund MC; Carstam R; Hansson C; Rorsman H; Rosengren E
Acta Derm Venereol; 1985; 65(5):437-9. PubMed ID: 2416171
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children.
Meyerhöffer S; Lindberg Z; Häger A; Kågedal B; Rosdahl I
Acta Derm Venereol; 1998 Jan; 78(1):31-5. PubMed ID: 9498023
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of 6-hydroxy-5-methoxyindole-2-carboxylic acid and 5-S-cysteinyldopa during PUVA treatment.
Hansson C; Wirestrand LE; Aronsson A; Rorsman H; Rosengren E
Photodermatol; 1985 Apr; 2(2):52-7. PubMed ID: 3929237
[TBL] [Abstract][Full Text] [Related]
15. Correlation between urinary melanin-related metabolites and tumour weight in melanoma-bearing mice.
Ito S; Wakamatsu K; Inoue S; Fujita K
Acta Derm Venereol; 1989; 69(5):380-4. PubMed ID: 2572100
[TBL] [Abstract][Full Text] [Related]
16. [Eumelanin and pheomelanin contents in hairs of healthy Japanese and patients with oculocutaneous albinism, and 5-S-cysteinyldopa and 5-hydroxy-6-methoxyindole-2-carboxylic acid levels in urine of oculocutaneous albinism].
Saito N; Morishima T
Nihon Hifuka Gakkai Zasshi; 1990 Jul; 100(8):853-61. PubMed ID: 2122048
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
18. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma.
Hara H; Walsh N; Yamada K; Jimbow K
J Invest Dermatol; 1994 Apr; 102(4):501-5. PubMed ID: 8151128
[TBL] [Abstract][Full Text] [Related]
19. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of melanin-related metabolites as markers of solar ultraviolet-B radiation.
Wakamatsu K; Ito S
Pigment Cell Res; 2006 Oct; 19(5):460-4. PubMed ID: 16965276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
